Notify me when Commodore Capital LP files a new 13F portfolio report.
⭐ Subscribe ⭐| Quarter | Holdings | Value $ | Bought | Sold | Net | Top Holdings | Form Type | Filing Time |
|---|---|---|---|---|---|---|---|---|
| Q3 2025 | 37 | $2,048,436,266 | +$361,796,321 | -$229,917,295 | +$131,879,026 | MRUS, NUVL, XENE, COGT, ELVN | 13F-HR | 14 Nov 2025, 16:10 |
| Q2 2025 | 33 | $1,416,719,296 | +$328,166,414 | -$357,668,291 | -$29,501,877 | MRUS, NUVL, XENE, ELVN, AGIO | 13F-HR | 14 Aug 2025, 16:36 |
| Q1 2025 | 31 | $1,357,083,846 | +$292,196,506 | -$71,517,205 | +$220,679,301 | MRUS, NUVL, ELVN, SLNO, XENE | 13F-HR | 15 May 2025, 16:00 |
| Q4 2024 | 31 | $1,364,557,313 | +$305,311,153 | -$360,138,258 | -$54,827,105 | MRUS, PCVX, NUVL, XENE, ELVN | 13F-HR | 14 Feb 2025, 16:07 |
| Q3 2024 | 36 | $1,600,269,489 | +$182,219,512 | -$226,688,734 | -$44,469,222 | MRUS, VERA, XENE, PCVX, ELVN | 13F-HR | 14 Nov 2024, 15:45 |
| Q2 2024 | 35 | $1,465,008,171 | +$311,596,306 | -$240,179,913 | +$71,416,393 | MRUS, NUVL, XENE, PCVX, ELVN | 13F-HR | 14 Aug 2024, 16:25 |
| Q1 2024 | 38 | $1,468,388,968 | +$300,342,924 | -$296,302,111 | +$4,040,813 | MRUS, VERA, NUVL, XENE, SYRE | 13F-HR | 15 May 2024, 16:05 |
| Q4 2023 | 32 | $1,144,464,541 | +$272,032,596 | -$167,234,938 | +$104,797,658 | MRUS, XENE, NUVL, VERA, RYTM | Restatement | 14 Feb 2024, 16:38 |
| Q3 2023 | 33 | $840,509,177 | +$153,938,217 | -$119,541,865 | +$34,396,352 | MRUS, VERA, XENE, PCVX, COGT | 13F-HR | 14 Nov 2023, 16:00 |
| Q2 2023 | 34 | $889,839,183 | +$223,081,880 | -$132,878,611 | +$90,203,269 | MRUS, VERA, AKRO, XENE, COGT | 13F-HR | 14 Aug 2023, 17:00 |
| Q1 2023 | 32 | $656,834,859 | +$170,942,983 | -$43,706,156 | +$127,236,827 | XENE, VRDN, MRUS, COGT, BLU | 13F-HR | 15 May 2023, 16:06 |
| Q4 2022 | 35 | $663,544,000 | +$167,172,140 | -$45,952,486 | +$121,219,654 | XENE, VRDN, COGT, BLU, MRUS | 13F-HR | 14 Feb 2023, 10:00 |
| Q3 2022 | 28 | $597,869,000 | +$136,688,879 | -$21,985,661 | +$114,703,218 | COGT, XENE, VRDN, BLU, MRUS | 13F-HR | 14 Nov 2022, 15:00 |
| Q2 2022 | 23 | $469,066,000 | +$112,614,651 | -$19,403,355 | +$93,211,296 | MRUS, XENE, COGT, BLU, CYTK | 13F-HR | 15 Aug 2022, 17:02 |
| Q1 2022 | 27 | $447,722,000 | +$109,841,293 | -$34,250,758 | +$75,590,535 | MRUS, ACRS, BLU, ISEE, XENE | 13F-HR | 16 May 2022, 16:00 |
| Q4 2021 | 25 | $431,774,000 | +$131,307,261 | -$4,224,037 | +$127,083,224 | ISEE, MRUS, ACRS, XENE, CYTK | 13F-HR | 14 Feb 2022, 15:07 |
| Q3 2021 | 29 | $379,293,000 | +$137,271,150 | -$50,515,818 | +$86,755,332 | ISEE, ACRS, CYTK, DRNA, CCCC | 13F-HR | 15 Nov 2021, 16:02 |
| Q2 2021 | 29 | $287,021,000 | +$75,392,592 | -$45,829,723 | +$29,562,869 | ACRS, STSA, CELC, CCCC, CBAY | Restatement | 13 Oct 2021, 18:02 |
| Q1 2021 | 31 | $251,032,000 | +$74,305,143 | -$34,006,209 | +$40,298,934 | ACRS, CCCC, KURA, STSA, FPRX | Restatement | 13 Oct 2021, 17:58 |
| Q4 2020 | 28 | $183,931,000 | $0 | CCCC, TRILLIUM THERAPEUTICS INC, CNST, FPRX, KRON | 13F-HR | 16 Feb 2021, 15:13 |